Role of Innate and Adaptive Immune Systems in Drug-Induced Liver Disease
先天性和适应性免疫系统在药物性肝病中的作用
基本信息
- 批准号:8344879
- 负责人:
- 金额:$ 49.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:AcidsAdjuvantAnimal ModelAnimalsAntibodiesAnticonvulsantsAntigen-Presenting CellsAutoimmune DiseasesCategoriesCellsChloride IonChloridesClinicalDisulfiramDrug toxicityEndothelial CellsErythromycinEthanolFemaleHalothaneHepaticHepatocyteHumanImmuneImmune responseImmune systemInfectionInjuryKupffer CellsLiverMediatingMusMyelogenousPharmaceutical PreparationsPredispositionProcessProteinsReactionRegulatory T-LymphocyteReportingRoleSulfonamidesSuppressor-Effector T-LymphocytesT-Lymphocyteadductdrug induced liver diseaseimmunopathologyin vivopreventtroglitazonetumor
项目摘要
Last year we found that regulatory T cells infiltrated into the liver of female Balb/cJ mice following halothane treatment and inhibited both humoral and cellular immune reactions against trifluoroacetylated proteins formed in vivo following halothane treatment. This year we report that newly discovered myeloid-derived suppressor cells also infiltrated into the liver of female Balb/cJ mice following halothane treatment. These cells have be shown recently to inhibit effector T cell activity in tumors, infections, and in autoimmune diseases.
Conclusion: These findings suggest that both regulatory T cells and myeloid-derived suppressor cells might have a role in preventing drug-protein adducts from causing liver injury mediated by the adaptive immune system and that deficiencies in the activities of these regulatory cells might be susceptibility factors in DILD.
去年,我们发现在氟烷治疗后,调节性 T 细胞渗入雌性 Balb/cJ 小鼠的肝脏,并抑制针对氟烷治疗后体内形成的三氟乙酰化蛋白的体液和细胞免疫反应。 今年,我们报告新发现的骨髓源性抑制细胞在氟烷治疗后也渗入雌性 Balb/cJ 小鼠的肝脏中。最近显示这些细胞可以抑制肿瘤、感染和自身免疫性疾病中的效应 T 细胞活性。
结论:这些研究结果表明,调节性T细胞和髓源性抑制细胞可能在防止药物-蛋白加合物引起适应性免疫系统介导的肝损伤方面发挥作用,并且这些调节细胞活性的缺陷可能是DILD的易感因素。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lance R Pohl其他文献
Lance R Pohl的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lance R Pohl', 18)}}的其他基金
Role of Innate and Adaptive Immune Systems in Drug-Induced Liver Disease
先天性和适应性免疫系统在药物性肝病中的作用
- 批准号:
8558025 - 财政年份:
- 资助金额:
$ 49.54万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 49.54万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 49.54万 - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 49.54万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 49.54万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 49.54万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 49.54万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 49.54万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 49.54万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 49.54万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 49.54万 - 项目类别:














{{item.name}}会员




